Archives
Berberine Suppresses SASP-Driven Inflammation via RXRα/PPARγ
2026-07-22
Berberine Suppresses SASP-Driven Inflammation via RXRα/PPARγ/NEDD4 in Atherosclerosis
Study Background and Research Question
Chronic inflammation driven by the accumulation of senescent cells is a recognized contributor to atherosclerosis and related cardiovascular diseases. Senescent cells display the senescence-associated secretory phenotype (SASP), marked by sustained release of pro-inflammatory cytokines, chemokines, and matrix remodeling factors that perpetuate tissue dysfunction. Particularly, macrophage-derived foam cells within atherosclerotic plaques are key mediators of this inflammatory aging process. Despite the clinical significance, the molecular mechanisms by which SASP is regulated in atherosclerosis, and how it might be therapeutically targeted, remain incompletely defined. The current reference study (Zheng et al., 2025) addresses this gap by dissecting how berberine (BBR), a bioactive isoquinoline alkaloid, modulates SASP-related inflammation through the RXRα/PPARγ/NEDD4 axis in cellular and murine models of atherosclerosis.Key Innovation from the Reference Study
The study's central innovation lies in the identification of a coordinated signaling mechanism involving RXRα (Retinoid X Receptor alpha), PPARγ (Peroxisome Proliferator-Activated Receptor gamma), and NEDD4 (E3 ubiquitin ligase) as a pivotal regulatory pathway for SASP-driven inflammation in atherosclerosis. Prior research has implicated both RXRα and PPARγ in lipid metabolism and inflammatory processes, but their integration with NEDD4-mediated ubiquitination of the GATA4/p62 complex, as demonstrated here, represents a novel mechanistic bridge between nuclear receptor signaling and the control of pro-inflammatory aging phenotypes. This finding not only enhances our understanding of berberine's anti-atherosclerotic actions but also establishes a foundation for targeted modulation of the RXRα/PPARγ/NEDD4 axis in vascular inflammation (reference study).Methods and Experimental Design Insights
The study employed a multi-tiered experimental approach:- In vivo modeling: ApoE knockout (ApoE-/-) mice were subjected to high-fat diets to induce atherosclerotic plaque formation. Berberine was administered to evaluate its effects on plaque morphology, blood chemistry, and inflammatory status.
- Cellular models: RAW264.7 murine macrophages and peritoneal macrophage-derived foam cells were used to probe SASP marker expression and inflammatory protein production in response to berberine treatment.
- Pathway interrogation: Smart-seq single-cell sequencing enabled transcriptomic profiling of atherosclerotic plaques, identifying key signaling changes post-berberine intervention.
- Genetic manipulation: Lentivirus-mediated knockdown of RXRα in macrophages (via pLVCD68-shRNA RXRα) tested the necessity of RXRα for berberine's anti-inflammatory effect.
- Molecular assays: Immunoprecipitation and Western blotting determined protein-protein interactions, ubiquitination status, and the role of the GATA4/p62 complex in SASP regulation.
Core Findings and Why They Matter
The main findings can be summarized as follows:- Berberine reduces SASP-driven inflammation: Both in vivo and in vitro, berberine significantly suppressed SASP-associated cytokine production in atherosclerotic lesions and macrophage-derived foam cells (reference study).
- Activation of the RXRα/PPARγ/NEDD4 axis: Transcriptomic and protein analyses revealed that berberine enhances RXRα and PPARγ activity, leading to upregulation of NEDD4. This, in turn, promotes ubiquitination and degradation of the GATA4/p62 complex—a key driver of SASP protein expression.
- RXRα is essential for berberine's effect: Knockdown of RXRα in macrophages abrogated the anti-inflammatory and anti-atherosclerotic actions of berberine, confirming the requirement for RXRα-PPARγ coactivation in this pathway.
- Translational relevance: The data indicate that targeting the RXRα/PPARγ/NEDD4 pathway can mitigate inflammatory aging in vascular disease, providing a rational basis for future therapeutic strategies.
Comparison with Existing Internal Articles
Multiple internal articles have explored the relevance of PPARγ antagonists and signaling pathway inhibitors in the context of cellular aging, adipogenesis, and inflammation. For example, the article "T0070907: PPARγ Antagonist Unlocking New Frontiers in Cellular Aging Research" emphasizes how selective PPARγ antagonists like T0070907 can help delineate the RXRα/PPARγ/NEDD4 axis, supporting pathway dissection in models of SASP and inflammation. Similarly, "T0070907: Precision PPARγ Antagonist for Adipogenesis & SASP Studies" provides workflow guidance for using pathway-specific inhibitors to validate the roles of nuclear receptors in senescence and inflammatory signaling. These articles bridge the mechanistic insights from the berberine study by offering practical tools and protocols for targeting the same signaling axis in diverse cellular models. Notably, T0070907's ability to inhibit PPARγ with nanomolar potency (internal resource) makes it highly relevant for functional validation of pathway dependencies observed in the reference study.Limitations and Transferability
While the reference study demonstrates a clear mechanistic link between berberine, RXRα/PPARγ/NEDD4 signaling, and SASP attenuation in atherosclerosis, several caveats should be noted:- Species and model limitations: The in vivo findings are based on ApoE-/- mice, which, while widely used, do not recapitulate all aspects of human atherosclerosis.
- Cell-type specificity: The centrality of macrophage-derived foam cells highlights the importance of tissue and cell context; whether similar mechanisms operate in other senescent cell types remains to be determined.
- Therapeutic translation: The study establishes mechanistic proof-of-concept but does not address pharmacokinetics, safety, or efficacy of berberine or pathway inhibitors in clinical settings.
Protocol Parameters
- Macrophage-derived foam cell modeling: Use RAW264.7 or primary peritoneal macrophages loaded with ox-LDL to induce foam cell formation and SASP marker expression.
- Berberine treatment: Typical concentrations range from 5–50 μM in vitro; titrate for optimal inhibition of SASP-associated cytokines in pilot assays.
- PPARγ antagonist (e.g., T0070907) intervention: Literature supports nanomolar dosing (1–100 nM) for robust inhibition of PPARγ-dependent transcriptional activity (see workflow guidance).
- RXRα knockdown: Lentivirus encoding shRNA targeting RXRα is introduced into macrophages prior to foam cell formation or berberine exposure to test pathway specificity.
- Smart-seq transcriptomics: Apply single-cell RNA sequencing to plaque regions or cell populations after experimental manipulations to profile pathway activation and SASP marker changes.